Wyniki wyszukiwania - Biblioteka Nauki

1

Aliskiren – pierwszy przedstawiciel nowej grupy leków hipotensyjnych

100%

Jobs K. , Jung A.

Pediatria i Medycyna Rodzinna

|

2009

|

tom 5

|

nr 2

80-82

EN

Aliskiren is the first in a new class of antihypertensives – the direct renin inhibitors. It took a long time to discover it, mainly because of difficulties with creating an oral form with good bioavailability. It has been approved for the treatment of primary hypertension in United States and Europe in 2007. It provides good blood pressure efficacy, has good tolerability and small amount of undesirable side effects. Blocking renin, it prevents conversion of angiotensinogen to angiotensin I. First clinical trials concerning its use alone or in combination with ACEI or ARB give hope for greater reduction in blood pressure and more renal and cardiovascular protection that provided by ACEIs and ARBs. The ongoing clinical trial programme ASPIRE HIGHER will investigate the potential of aliskiren in improvement of renal and cardiovascular protection. Preliminary results are very promising. Aliskiren diminishes plasma renin activity from 50 to 80% in hypertensive patients after oral administration. It diminishes systolic and diastolic blood pressure. After single dose the effect of the drug lasts for 24 hours. Whole therapeutic effect is observed after two weeks.

PL

Aliskiren jest pierwszym przedstawicielem nowej grupy leków hipotensyjnych – bezpośrednich inhibitorów reniny. Badania nad jego powstaniem trwały długo, głównie z powodu trudności z uzyskaniem preparatu o dobrej biodostępności formy doustnej. W 2007 roku został dopuszczony do leczenia pierwotnego nadciśnienia tętniczego w Stanach Zjednoczonych i krajach Unii Europejskiej. Jest skutecznym lekiem hipotensyjnym, o małej liczbie działań ubocznych i dobrej tolerancji. Blokując reninę, zapobiega konwersji angiotensynogenu do angiotensyny I. Pierwsze badania kliniczne z jego wykorzystaniem dają nadzieję na addytywny efekt hipotensyjny i nefro- oraz kardioprotekcyjny, w przypadku połączenia go z inhibitorami konwertazy (ACEI) lub antagonistami receptora dla angiotensyny II (ARB). Podobnego efektu nie wykazano dla połączenia tycw dwóch grup leków. Największym, trwającym właśnie badaniem nad wykorzystaniem aliskirenu w udoskonaleniu nefro- i kardioprotekcji jest badanie ASPIRE HIGHER. Obejmuje ono ponad 35 tysięcy chorych, z planowanym okresem leczenia ponad 6 lat, i ma na celu sprawdzenie potencjalnej wyższości leku w zakresie działania nefroprotekcyjnego w porównaniu z ACEI i ARB. Wstępne wyniki wskazują na jego duży potencjał kardio- i nefroprotekcyjny. Po podaniu doustnym u chorych z nadciśnieniem zmniejsza on aktywność reninową osocza z 50 do 80%. Lek obniża wartość ciśnienia skurczowego i rozkurczowego, a działanie pojedynczej dawki utrzymuje się przez 24 godziny. Pełne działanie terapeutyczne osiąga po dwóch tygodniach.

2

Urocortin 2 in patients with hypertension treated with angiotensin converting enzyme inhibitors or angiotensin receptor blockers

100%

Walczewska J. , Siga O. , Dziezga-Grudnik A. , Krolczyk J. , Wizner B. , Wolkow P. P. , Borys A. , Kolton-Wroz M. , Gryglewska B. , Grodzicki T.

Journal of Physiology and Pharmacology

|

2019

|

tom 70

|

nr 2

3

The role of peroxisome-proliferator-activating receptor gamma agonists: rosiglitazone and 15-deoxy-delta12,14-prostaglandin J2 in chronic experimental cyclosporine A-induced nephrotoxicity

100%

Korolczuk A. , Maciejewski M. , Smolen A. , Dudka J. , Czechowska G. , Widelska I.

Journal of Physiology and Pharmacology

|

2014

|

tom 65

|

nr 6

4

Spironolactone, but not enalapril, potentiates hypoxia-inducible factor-1alpha and Ets-1 expression in newborn rat kidney

80%

Yim H. E. , Kim J. H. , Yoo K. H. , Bae I. S. , Jang G. Y. , Hong Y. S. , Lee J. W.

Journal of Physiology and Pharmacology

|

2010

|

tom 61

|

nr 1

73-81

EN

Hypoxia is regarded as an important physiological factor that controls nephrogenesis. We investigated whether the renin-angiotensin-aldosterone system (RAAS) affects hypoxia-related target genes in developing kidneys. Newborn rat pups were treated with enalapril (30 mg/kg/d) or spironolactone (200 mg/kg/d) for 7 days. Tissue hypoxia was assessed by the uptake of a hypoxyprobe-1, pimonidazole (200 mg/kg), and the expression of hypoxia-responsive genes. In the enalapril group, hypoxia-inducible factor (HIF)-1, HIF-2, and Ets-1 protein expression were not changed, compared to the control group. In the spironolactone group, HIF-1 and Ets-1 protein expression were significantly increased by immunoblots and immunohistochemistry, whereas HIF-2 protein expression was not changed, compared to the control group. In the enalapril group, the immunoactivity of pimonidazole was not significantly different from that of the controls. However, in the spironolactone group, pimonidazole staining demonstrated that the cortex and medulla underwent severe hypoxia. In summary, our data showed that aldosterone inhibition in the developing kidney augmented the hypoxic responses, and up-regulated the expression of key mediators of hypoxia including HIF-1 and Ets-1. Angiotensin II inhibition did not affect hypoxia-related alterations in the developing kidney. The components of RAAS may differentially modulate renal hypoxia and its related target genes in the developing rat kidney.

5

Renin - angiotensin - aldosterone system versus osmotic pressure of blood plasma in calves in the neonatal period

80%

Ozgo M.

Electronic Journal of Polish Agricultural Universities. Series Veterinary Medicine

|

2001

|

tom 04

|

nr 2

6

The expression of the renin-angiotensin-aldosterone system in the skin and its effects on skin physiology and pathophysiology

80%

Aleksiejczuk M. , Gromotowicz-Poplawska A. , Marcinczyk N. , Przylipiak A. , Chabielska E.

Journal of Physiology and Pharmacology

|

2019

|

tom 70

|

nr 3

7

Ramipril affects hydrogen sulfide generation in mouse liver and kidney

80%

Wilinski B. , Wilinski J. , Somogyi E. , Goralska M. , Piotrowska J.

Folia Biologica

|

2010

|

tom 58

|

nr 3-4

177-180

8

Central TNF-alpha elevates blood pressure and sensitizes to central pressor action of angiotensin II in the infarcted rats

80%

Zera T. , Ufnal M. , Szczepanska-Sadowska E.

|

tom 59

|

nr 8

9

Gene polymorphisms of the renin-angiotensin-aldosterone system and essential arterial hypertension in childhood

80%

Petrovic D. , Bidovec M. , Peterlin B.

Folia Biologica

|

2002

|

tom 50

|

nr 1-2

10

Nifedipine inhibits the hypoxia-induced decrease in plasma renin activity in conscious dogs

80%

Hohne C. , Arntz E. , Krebs M. O. , Boemke W. , Kaczmarczyk G.

Journal of Physiology and Pharmacology

|

2003

|

tom 54

|

nr 2

EN

Acute hypoxia induces a decrease in plasma renin activity (PRA), mediated, e.g., by an increase in adenosine concentration, calcium channel activity, or inhibition of ATP-sensitive potassium channels. The decrease in PRA results in a decrease in angiotensin II (AngII) and plasma aldosterone concentration (PAC). This study investigates whether these hypoxia-induced mechanisms can be inhibited by the L-type voltage-dependent calcium channel antagonist nifedipine. Eight conscious, chronically tracheotomized dogs received a low sodium diet (0.5 mmol Na·kg body wt-1·day-1). The dogs were studied twice in randomized order, either with nifedipine infusion (1.5 µg·kg body wt-1·min-1, Nifedipine) or without (Control). The dogs were breathing spontaneously: first hour, normoxia [inspiratory oxygen fraction (FiO2)=0.21]; second and third hour hypoxia (FiO2=0.1). In Controls, PRA (6.8±0.8 vs. 3.0±0.5 ngAngI·ml-1·min-1), AngII (13.3±1.9 vs. 7.3±1.9 pg/ml), and PAC (316±50 vs. 69±12 pg/ml) decreased during hypoxia (P<0.05). In Nifedipine experiments, PRA (6.5±0.9 vs. 10.5±2.4 ngAngI·ml-1·min-1) and AngII (14±1.1 vs. 18±3.9 pg/ml) increased during hypoxia, whereas the decrease in PAC (292±81 vs. 153±41 pg/ml) was blunted (P<0.05). These results foster the idea that the hypoxia-induced decrease in PRA involves L-type calcium channel activity.

11

Jak osiągnąć równowagę u pacjentów z chorobą układu sercowo-naczyniowego i chorobą nerek?

61%

Cook A. K. , Saunders A. B.

Weterynaria po Dyplomie

|

2019

|

tom 20

|

nr 6